publication venue for
- Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City. 106:79-88. 2019
- Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?. 105:37-43. 2019
- Establishing the feasibility, acceptability and preliminary efficacy of a multi-component behavioral intervention to reduce pain and substance use and improve physical performance in older persons living with HIV. 100:29-38. 2019
- Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. 81:66-72. 2017
- Monetary conversion factors for economic evaluations of substance use disorders. 81:25-34. 2017
- Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders. 78:37-42. 2017
- Quality of life as an outcome of opioid use disorder treatment: A systematic review. 76:88-93. 2017
- Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population 2017
- Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? 2016
- Examining Longitudinal Stimulant Use and Treatment Attendance as Parallel Outcomes in Two Contingency Management Randomized Clinical Trials. 61:18-25. 2016
- Determinants of buprenorphine treatment for opioid dependence. 46:315-9. 2014
- Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. 44:115-9. 2013
- Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. 42:438-45. 2012
- Adapting problem-solving therapy for depressed older adults in methadone maintenance treatment. 40:132-41. 2011
- Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: The National Drug Abuse Treatment Clinical Trials Network. 30:315-21. 2006
- Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance. 30:331-5. 2006
- Concluding remarks 1985